Skip to main content
SpringerLink
Log in

Targeted Magnetic Resonance Imaging Contrast Agents

  • Chapter
Targeted Molecular Imaging in Oncology

  • 178 Accesses

Abstract

Magnetic resonance (MR) contrast agents have been used to improve detection of lesions (better contrast-to-noise ratio) or to improve their characterization by changing tissue signal intensity. The more specific the accumulation of a contrast agent within the target tissue, the better the lesion-to-tissue contrast. Ideally, the target should be an organ of sufficient size with a large number of specific binding sites and also have a high blood flow. Target-specific molecules are called vectors, and “the carrier” means a compound-containing vector. Typical carrier systems include antibodies, proteins, peptides, polysaccharides, cells, and liposomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wang SC, Wikström MG, White DL, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent. Radiology 1990;175:483–488.

    PubMed  CAS  Google Scholar 

  2. Voxler VS, Clement O, Schmitt-Willich H, et al. Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. J Magn Reson Imaging 1994;4:381–388.

    Article  Google Scholar 

  3. Brasch RC New directions in the development of MR imaging contrast media. Radiology 1992; 183:1–11.

    PubMed  CAS  Google Scholar 

  4. Leander P. Liver-specific contrast media for MRI and CT experimental studies. Acta Radiol Suppl 1995;396:1–36.

    PubMed  CAS  Google Scholar 

  5. Weissleder R, Papisov M. Pharmaceutical iron oxides for MRI. J Magn Reson Imaging 1992; 4:1–6.

    Google Scholar 

  6. Shen T, Weissleder R, Papisov M, et al. Mono-crystalline iron oxide nanocompounds (MION). Magn Reson Med 1993;29:599–604.

    Article  PubMed  CAS  Google Scholar 

  7. Orang-Khadivi K, Pierce BL, Ollom CM, et al. New magnetic resonance imaging techniques for the detection of breast cancer. Breast Cancer Res Treat 1994;32:119–135.

    Article  PubMed  CAS  Google Scholar 

  8. Stenzel-Johnson PR, Yelton D, Bajorath J, et al. Identification of residues in the monoclonal antibody L6 important for binding to its tumor antigen. Biochemistry 1994;33:14400–14406.

    Article  PubMed  CAS  Google Scholar 

  9. Weissleder R, Lee AS, Khaw BA. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infract. Radiology 1991;181: 245–249.

    PubMed  CAS  Google Scholar 

  10. Schaffer BK, Linder C, Papisov M, et al. MION-ASF: biokinetics of an MR receptor agent. Magn Reson Imaging 1993;11:411–417.

    Article  PubMed  CAS  Google Scholar 

  11. Reimer P, Weissleder R, Wittenberg J, et al. Receptor-directed contrast agents for MRI. Radiology 1992;182:565–569.

    PubMed  CAS  Google Scholar 

  12. van Everdingen KJ, Enochs WS, Bhide PG, et al. Determinants of in vivo MRI of slow axonal transport. Radiology 1994;193:485–591.

    PubMed  Google Scholar 

  13. Reimer P, Weissleder R, Shen T, et al. Pancreatic receptors: initial feasibility studies with a target contrast agent for MRI. Radiology 1994;193: 527–531.

    PubMed  CAS  Google Scholar 

  14. Weissleder R, Papisov M. Pharmaceutical oxides for MRI. Rev Magn Reson Med 1992;4:1–20.

    Google Scholar 

  15. Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography. Radiology 1994;191:225–230.

    PubMed  CAS  Google Scholar 

  16. Vassallo P, Matei C, Heston WD, et al. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 1994;193:501–506.

    PubMed  CAS  Google Scholar 

  17. Harika L, Weissleder R, Poss K, et al. MR lymphography with a lymphotropic Tl-type MR contrast agent: Gd-DTPA-PGM. Magn Reson Med 1995;33:88–92.

    Article  PubMed  CAS  Google Scholar 

  18. Reimer P, Weissleder R, Brady TJ, et al. Experimental hepatocellular carcinoma: MR receptor imaging. Radiology 1991;180:641–645.

    PubMed  CAS  Google Scholar 

  19. Weissleder R, Wang YM, Papisov M, et al. Polymeric contrast agents for MRI of adrenal glands. J Magn Reson Imaging 1993;3:93–97.

    Article  PubMed  CAS  Google Scholar 

  20. Mühler A, Platzek J, Radüchel B, et al. Characterization of a Gd-cholesterol derivative as an organ specific contrast agent of adrenal imaging. J Magn Reson Imaging 1995;5:7–10.

    Article  PubMed  Google Scholar 

  21. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–1887.

    Article  PubMed  CAS  Google Scholar 

  22. Niesman MR, Bacic GG, Wright SM, et al. Liposome encapsulated MnCl2 as a liver specific contrast agent for MRI. Invest Radiol 1990;25: 545–551.

    Article  PubMed  CAS  Google Scholar 

  23. Yeh T, Zhang W, Ilstad ST, et al. Intracellular labeling of T-cells with superparamagnetic contrast agents. Magn Reson Med 1993;30:617–625.

    Article  PubMed  CAS  Google Scholar 

  24. Bulte JWM, Ma LD, Magin RL, et al. Selective MRI of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med 1993;29:32–37.

    Article  PubMed  CAS  Google Scholar 

  25. Mahfouz A-E, Hamm B. Contrast agents. MRI Clin North Am 1997;5:223–240.

    CAS  Google Scholar 

  26. Petersein J, Saini S, Weissleder R. Iron oxide-based reticuloendothelial contrast agents for MRI. MRI Clin North Am 1996;4:53–60.

    CAS  Google Scholar 

  27. Weissleder R, Reimer P, Lee AS, et al. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR 1990;155:1161–1167.

    Article  PubMed  CAS  Google Scholar 

  28. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MRI. Radiology 1990;175:489–493.

    PubMed  CAS  Google Scholar 

  29. Ros PR, Freeny PC, Harms SE, et al. Hepatic MRI with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481–488.

    PubMed  CAS  Google Scholar 

  30. Kopp AF, Laniado M, Dammann F, et al. MRI of the liver with Resovist: safety, efficacy and pharmacodynamic properties. Radiology 1997;204: 749–756.

    PubMed  CAS  Google Scholar 

  31. Shamsi K, Balzer T, Saini S, et al. Superparamagnetic iron oxide particles (SH U 555A): evaluation of efficacy in three doses for hepatic MRI. Radiology 1998;206:365–371.

    PubMed  CAS  Google Scholar 

  32. Vogl TJ, Hammerstingl R, Schwartz W, et al. Superparamagnetic iron oxide-enhanced versus Gd-enhanced MRI for differential diagnosis of focal liver lesions. Radiology 1996;198:881–887.

    PubMed  CAS  Google Scholar 

  33. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide (USPIO): an intravenous contrast agent for assessing lymph nodes with MRI. Radiology 1990;175:494–498.

    PubMed  CAS  Google Scholar 

  34. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995;164:1147–1152.

    Article  PubMed  CAS  Google Scholar 

  35. Mergo PJ, Helmberger T, Nicolas AL Ring enhancement in ultrasmall superparamagnetic iron oxide MRI: a potential new sign for characterization of liver lesions. AJR 1996;166:379–384.

    Article  PubMed  CAS  Google Scholar 

  36. Mitchell DG, Outwater EK, Matteucci T, et al. Adrenal gland enhancement at MRI with Mn-DPDP. Radiology 1995;194:783–787.

    PubMed  CAS  Google Scholar 

  37. Wang C, Ahlstrom H, Eriksson B, et al. Uptake of mangafodipir trisodium in liver metastases from endocrine tumors. J Magn Reson Imaging 1998;8:682–686.

    Article  PubMed  CAS  Google Scholar 

  38. Rofsky NM, Weinref JC, Bernardin ME, et al. Hepatocellular tumors: characterization with Mn-DPDP-enhanced MRI. Radiology 1993;188: 53–59.

    PubMed  CAS  Google Scholar 

  39. Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MRI with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69–77.

    PubMed  CAS  Google Scholar 

  40. Oksendal AN, Hals PA. Biodistribution and toxicity of MRI contrast media. J Magn Reson Imaging 1998;3:157–165.

    Article  Google Scholar 

  41. Runge VM. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Asst Tomogr 1998; 22:643–650.

    Article  CAS  Google Scholar 

  42. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology 1998;207:529–538.

    PubMed  CAS  Google Scholar 

  43. Grist TM, Korosec FR, Peters DC, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998;207:539–544.

    PubMed  CAS  Google Scholar 

  44. Schmiedl U, Sievers RE, Brasch RC, et al. Acute myocardial ischemia and reperfusion: MRI with albumin-Gd-DTPA. Radiology 1989;170:351–356.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Edmund Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Nuclear Medicine and Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, 77030, Houston, TX, USA

    E. Edmund Kim MD  & David J. Yang PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kim, E.E. (2001). Targeted Magnetic Resonance Imaging Contrast Agents. In: Kim, E.E., Yang, D.J. (eds) Targeted Molecular Imaging in Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-3505-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-3505-5_12

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-3507-9

  • Online ISBN: 978-1-4757-3505-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation